Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ5S9C)

Drug Name
MEDI-552 Drug Info
Synonyms B-cell depleting anti-CD20 monoclonal antibody, Cellective; B-cell depleting anti-CD20 monoclonal antibody, MedImmune
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
TTD Drug ID
DMQ5S9C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [2]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [3]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [4]
Ibritumomab DMG594T Non-hodgkin lymphoma 2B33.5 Approved [5]
Rituximab DM1YVZT Central nervous system non-hodgkin lymphoma Approved [6]
Ublituximab DMHTY9W Multiple sclerosis 8A40 Approved [7]
Tositumomab DMMYZ3D Non-hodgkin lymphoma 2B33.5 Approved [5]
Obinutuzumab DM3BVAE Chronic lymphocytic leukaemia 2A82.0 Approved [8]
Ofatumumab DM295PR Chronic lymphocytic leukaemia 2A82.0 Approved [9]
Rituximab DM1YVZT Central nervous system non-hodgkin lymphoma Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Modulator [1]

References

1 Anti CD37 antibodies
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
4 Clinical pipeline report, company report or official report of Genmab.
5 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
6 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
7 The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
9 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
10 Clinical pipeline report, company report or official report of Genentech (2009).